Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research At The American Society Of Hematology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics, Inc. (NASDAQ:BNGO) announced its participation in the American Society of Hematology (ASH) Annual Meeting with presentations and posters featuring the utility of optical genome mapping (OGM) in blood cancer research. Dr. Enze Liu will present a study on OGM's ability to detect structural variants in multiple myeloma. The conference, held in San Diego and online from December 9-12, 2023, will include 13 posters on OGM applications in various hematological conditions.
December 06, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bionano Genomics will present significant research on OGM in blood cancer at the ASH Annual Meeting, potentially highlighting the company's expertise and advancing its reputation in the medical research community.
The company's active role and the breadth of research being presented at a prestigious conference like ASH could positively influence investor perception and potentially lead to increased interest in Bionano's technology. This may result in a short-term positive impact on BNGO's stock price as the market reacts to the potential implications of OGM in blood cancer research and its future commercial applications.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100